Slovakia - Slovak - Ecolab

ecolab deutschland gmbh -

Slovakia - Slovak - Ecolab

ecolab deutschland gmbh -

Slovakia - Slovak - Ecolab

ecolab deutschland gmbh -

Slovakia - Slovak - Ecolab

ecolab deutschland gmbh -

European Union - Slovak - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - prípravky proti obezite, okrem diétne výrobky - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Slovakia - Slovak - ŠÚKL (Štátny ústav pre kontrolu liečiv)

ge healthcare buchler gmbh & co. kg, nemecko - terapeutické rádiofarmaká - 88 - radiopharmaca

European Union - Slovak - EMA (European Medicines Agency)

ceva santé animale - oslabený živý vírus vakcíny proti besnote, kmeň spbn gasgas - immunologicals pre canidae, Živé vírusové vakcíny - red foxes (vulpes vulpes); raccoon dogs (nyctereutes procyonoides) - na aktívnu imunizáciu líšok a psíkov mýval proti besnote, aby sa zabránilo infekcii a úmrtnosti.

European Union - Slovak - EMA (European Medicines Agency)

mylan ire healthcare limited - fondaparinux sodný - venous thrombosis; pulmonary embolism; myocardial infarction; angina, unstable - antitrombotické činidlá - 5 mg / 0. 3 ml a 2. 5 mg / 0. 5-ml solution for injectionprevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery. prevencia vte u dospelých podstupujúcich brušnej chirurgie, ktorí sa súdia, aby sa na vysoké riziko thromboembolic komplikácie, ako u pacientov podstupujúcich brušnej operácii rakoviny. prevencia vte u dospelých pacientov, ktorí sa súdia, aby sa na vysoké riziko vte a ktorí sú imobilizované v dôsledku akútnej choroby, ako sú srdcová nedostatočnosť a / alebo akútne respiračné poruchy a / alebo akútne zápalové ochorenie infekčnej alebo. liečbu dospelých pacientov s akútnym príznakom spontánne povrchné-žilová trombóza dolných končatín bez súčasné hlboké-žilová trombóza. 5 mg / 0. 5-ml solution for injectiontreatment of unstable angina or non-st-segment-elevation myocardial infarction (ua/nstemi) in adult patients for whom urgent (< 120 mins) invasive management (pci) is not indicated. myokardu (stemi) u dospelých pacientov, ktorí sú spravované s thrombolytics alebo ktorí pôvodne sa dostať žiadna iná forma reperfusion therapy. 5 mg / 0. 4-ml, 7. 5 mg / 0. 6-ml a 10 mg/0. 8-ml solution for injectiontreatment of adults with acute deep-vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

European Union - Slovak - EMA (European Medicines Agency)

sandoz gmbh - pemetrexed disodný hemipentahydrát - carcinoma, non-small-cell lung; mesothelioma - antineoplastické činidlá - malígny pleurálna mesothelioma pemetrexed sandoz v kombinácii s cisplatin je indikovaný na liečbu chemoterapiou naivných pacientov s unresectable malígny pleurálna mesothelioma. non-small cell lung cancer pemetrexed sandoz v kombinácii s cisplatin je uvedené, za prvé-line liečbu pacientov s lokálne pokročilým alebo metastatickým non-small cell lung cancer iné ako prevažne dlaždicových buniek histology. pemetrexed sandoz je označené ako monotherapy pre udržiavaciu liečbu lokálne pokročilým alebo metastatickým non-small cell lung cancer iné ako prevažne dlaždicových buniek histology u pacientov, ktorých ochorenie nie postupoval bezprostredne po platinum-založené chemoterapia. pemetrexed sandoz je označené ako monotherapy pre druhý riadok liečbu pacientov s lokálne pokročilým alebo metastatickým non-small cell lung cancer iné ako prevažne dlaždicových buniek histology.

European Union - Slovak - EMA (European Medicines Agency)

merck sharp and dohme b.v - posakonazol - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimykotika na systémové použitie - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 a 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 a 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 a 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 a 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- invázne aspergillosis u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b alebo itraconazole alebo u pacientov, ktorí netolerujú týchto liekov;- fusariosis u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b alebo u pacientov, ktorí netolerujú z amphotericin b;- chromoblastomycosis a mycetoma u pacientov s ochorením, ktoré je žiaruvzdorných na itraconazole alebo u pacientov, ktorí netolerujú z itraconazole;- kokcidiomykóza u pacientov s ochorením, ktoré je žiaruvzdorných na amphotericin b, itraconazole alebo fluconazol alebo u pacientov, ktorí netolerujú týchto liekov;- oropharyngeal kandidóza: ako v prvej línii liečby u pacientov, ktorí majú závažné ochorenie alebo sú imunokompromitovaných, v ktorých reakcie na aktuálne terapia sa očakáva, že byť chudobným. refractoriness je definovaný ako priebeh infekcie alebo neschopnosť zlepšiť po minimálne 7 dní pred terapeutické dávky účinných protiplesňové terapia. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.